MIAMI, March 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that the Company’s Board of Directors has approved a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.001 per share and Class B common stock, par value $0.001 per share (the “common stock”) (the “Reverse Split”). The Reverse Split was previously approved by
Longeveron ( NASDAQ:LGVN ) Full Year 2023 Results Key Financial Results Net loss: US$22.2m (loss widened by 18% from FY...
Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript February 27, 2024 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.25 EPS, expectations were $-0.21. FDS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, good afternoon, and […]